The CONVERGE study evaluates NBTXR3's efficacy in stage III unresectable NSCLC with standard chemoradiation and durvalumab. NBTXR3, a hafnium oxide nanoparticle, is activated by radiotherapy to induce ...

for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab ( NCT06667908). CONVERGE is ...